Tech Week Singapore 2025: Government leaders and tech giants converge to discuss the impact of AI

— Guest of Honour Mr Tan Kiat How, Senior Minister of State for Digital Development and Information will be speaking at the opening ceremony — Tech Week Shanghai 2026 to be unveiled at the inaugural Tech Night 2025, Tech Week Singapore's networking session that brings together notable speakers and key industry leaders from prominent organisations […]

InterDigital raises third quarter outlook

(NASDAQ:IDCC), New smartphone license agreement drives projected ARR1 to all-time high of $579 million WILMINGTON, Del., Sept. 22, 2025 (GLOBE NEWSWIRE) — InterDigital, Inc. (Nasdaq: IDCC), a mobile, video and AI technology research and development company, today announced that it has signed a new license agreement with a major Chinese smartphone vendor and has raised

European Medicines Agency Recommends Marketing Approval of Gobivaz(R), Alvotech’s Proposed Biosimilar to Simponi(R) (golimumab) with Advanz Pharma as Commercialization Partner

(NasdaqGM:ALVO),(Nasdaq First North Iceland:ALVO),(Stockholm:ALVO SDB), REYKJAVIK, ICELAND and LONDON, Sept. 22, 2025 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and

European Medicines Agency Recommends Marketing Approval of Gobivaz(R), Alvotech’s Proposed Biosimilar to Simponi(R) (golimumab) with Advanz Pharma as Commercialization Partner

European Medicines Agency Recommends Marketing Approval of Gobivaz(R), Alvotech's Proposed Biosimilar to Simponi(R) (golimumab) with Advanz Pharma as Commercialization Partner GlobeNewswire September 22, 2025 REYKJAVIK, ICELAND and LONDON, Sept. 22, 2025 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz

InterDigital raises third quarter outlook

InterDigital raises third quarter outlook GlobeNewswire September 22, 2025 New smartphone license agreement drives projected ARR1 to all-time high of $579 million WILMINGTON, Del., Sept. 22, 2025 (GLOBE NEWSWIRE) — InterDigital, Inc. (Nasdaq: IDCC), a mobile, video and AI technology research and development company, today announced that it has signed a new license agreement with

BC.GAME Launches Tap Trading, a Price-Touch Multiplier Game for Crypto Markets

BC.GAME, a global provider of online entertainment and crypto-native experiences, today announced the launch of Tap Trading(a touch-to-payout multiplier game) on its platform. At launch, Tap Trading will support multiple mainstream crypto pairs, including ETH/USDT, SOL/USDT, and STONKS/USDT. Users can access the product in the Web/App “Crypto Futures” section. https://mma.prnewswire.com/media/2778368/Tap_Trading.jpg BC.GAME already offers a diversified

UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit againstUnicycive Therapeutics, Inc. (“Unicycive” or “the Company”) (NASDAQ: UNCY) forviolations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's

SPPI Investors Have Opportunity to Lead Spectrum Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit againstSpectrum Pharmaceuticals, Inc. (“Spectrum” or “the Company”) (NASDAQ: SPPI)forviolations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. https://mma.prnewswire.com/media/1396534/Schall_Firm_Logo.jpg Investors who purchased the Company's

RxSight, Inc. Investigated for Securities Fraud Violations – Contact the DJS Law Group to Discuss Your Rights – RXST

The DJS Law Groupannounces that it is investigating claims on behalf of investors ofRxSight, Inc. (“RxSight” or “the Company”) (NASDAQ: RXST) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors. RxSight reported its financial results for the second

Luminar Technologies, Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – LAZR

The DJS Law Group reminds investors of a class action lawsuit against Luminar Technologies, Inc. (“Luminar” or “the Company”) (NASDAQ: LAZR ) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of LAZR during the class

Scroll to Top